HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin
- 30 November 2005
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 43 (5), 783-790
- https://doi.org/10.1016/j.jhep.2005.05.019
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combinationJournal of Hepatology, 2004
- Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon ??2b and ribavirin: an open-label series1Transplantation, 2004
- Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infectionAIDS, 2004
- 1204 Early HCV kinetics in immunosuppressed patients undergoing antiviral therapy: OLT vs. HIV-HCV coinfected vs. normal patientsHepatology, 2003
- 296 Importance of ribavirin dosage on virological response rates in patients chronically infected with hepatitis C virus and treated with interferon-based combination therapyHepatology, 2003
- Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV CoinfectionThe Journal of Infectious Diseases, 2003
- Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 casesHepatology, 2003
- Recent Advances in Liver TransplantationMayo Clinic Proceedings, 2003
- Treatment of recurrent hepatitis CLiver Transplantation, 2002
- DAILY INTERFERON THERAPY FOR HEPATITIS C VIRUS INFECTION IN LIVER TRANSPLANT RECIPIENTSTransplantation, 2001